Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
This article was originally published in The Pink Sheet
Executive Summary
OTC proton pump inhibitors should carry a warning that the products do not eliminate risks of esophageal cancer from persistent heartburn, says the Esophageal Cancer Action Network in a citizen petition to US FDA. FDA should “immediately” require the warning, which should be bold and prominent.
You may also be interested in...
GSK Consumer Leaving Costa Rica: Consumer Health News Roundup
GSK closing Costa Rica consumer product plant; PPI study authors suggest physicians’ counsel on OTC use; and Makesense topicals recall.
UK Notes PPI Dermatosis Risk: Will FDA Make Similar Communication?
The UK drug regulator announces “a very low risk” of sub-acute cutaneous lupus erythematosus from use of PPIs, which are available there with the same ingredients approved for use in the US in products available OTC and RX – esomeprazole, lansoprazole and omeprazole – and Rx only, pantoprazole and rabeprazole.
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.